AxoGen, Inc. (AXGN)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$48.28+2.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · AXGN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 251.2 | 225.2 | 187.3 | 159.0 | 138.6 | 127.4 | 112.3 | 106.7 | 83.9 | 60.4 | 41.1 | 27.3 | 16.8 | 10.9 | 7.7 | 4.8 |
| Total Revenues | 251.2 | 225.2 | 187.3 | 159.0 | 138.6 | 127.4 | 112.3 | 106.7 | 83.9 | 60.4 | 41.1 | 27.3 | 16.8 | 10.9 | 7.7 | 4.8 |
| Cost of Revenues | 63.9 | 57.9 | 45.4 | 37.1 | 29.8 | 22.9 | 21.6 | 17.3 | 12.9 | — | — | — | — | — | — | — |
| Gross Profit | 187.3 | 167.4 | 142.0 | 121.9 | 108.8 | 104.4 | 90.7 | 89.4 | 71.0 | 51.1 | 34.6 | 22.5 | 13.4 | 8.5 | 5.7 | 2.4 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 36.0 | 32.9 | 27.8 | 27.3 | 25.6 | 24.2 | 17.8 | 17.5 | 11.8 | 6.7 | 4.2 | 3.2 | 3.0 | 2.1 | 1.4 | 0.7 |
| Operating Income | (12.8) | (7.8) | (3.3) | (21.5) | (29.7) | (25.4) | (23.2) | (31.4) | (20.5) | (8.0) | (8.1) | (9.3) | (9.8) | (9.6) | (7.8) | (7.0) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 7.7 | 8.2 | 2.8 | 0.6 | 1.4 | 1.1 | 0.0 | 1.2 | 2.2 | 5.4 | 4.0 | 6.8 | 4.8 | 1.4 | 1.1 |
| Interest & Investment Income | — | — | — | — | — | — | — | 2.4 | 1.5 | — | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | — | — | — | — | (2.3) | (0.3) | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | (20.7) | (7.9) | (6.7) | (0.3) | 0.8 | (1.6) | (0.6) | 2.3 | (1.9) | (2.5) | (6.3) | (4.1) | (7.9) | (5.0) | (2.4) | (2.3) |
| EBT, Incl. Unusual Items | — | — | — | — | — | — | — | — | — | — | — | — | — | (14.6) | (10.2) | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (0.7) | — |
| Net Income | ||||||||||||||||
| Net Income | (33.5) | (15.7) | (10.0) | (21.7) | (28.9) | (27.0) | (23.8) | (29.1) | (22.4) | (10.4) | (14.4) | (13.4) | (17.7) | (14.6) | (9.4) | (9.2) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.63) | (0.34) | (0.23) | (0.51) | (0.69) | (0.65) | (0.60) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (0.63) | (0.34) | (0.23) | (0.51) | (0.69) | (0.65) | (0.60) | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 4.71 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 53.3 | 46.1 | 44.3 | 42.9 | 42.1 | 41.2 | 40.0 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 53.3 | 46.1 | 44.3 | 42.9 | 42.1 | 41.2 | 40.0 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (1.2) | 3.2 | (17.2) | (26.9) | (22.7) | (21.7) | — | — | — | — | — | (9.6) | (9.5) | (7.6) | — |
| EBIT | (12.8) | (7.8) | (3.3) | (21.5) | (29.7) | (25.4) | (23.2) | (31.4) | (20.5) | (8.0) | (8.1) | (9.3) | (9.8) | (9.6) | (7.8) | (7.0) |
| Effective Tax Rate | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0% | 7.3% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.